Is CCL18 a potential biomarker of type-2 asthma endotypes?

J Asthma. 2022 Mar;59(3):536-540. doi: 10.1080/02770903.2020.1861623. Epub 2020 Dec 18.

Abstract

Objective: This exploratory cross-sectional study aimed to evaluate the associations between the chemokine ligand 18 (CCL18) blood level and phenotypic characteristics of asthma.Methods: We evaluated in a sample of 173 asthmatic adult patients from the Cohort of Bronchial obstruction and Asthma (63.4% women; median age 50 ± interquartile range 27.5 years; median level of CCL18 was 44.1 ± interquartile range 27.5 ng/mL) the association between CCL18 blood level and allergic features of asthma using a multivariate analysis.Results: We found an association between the log-transformed value of blood CCL18 and age (+0.7% [0.1; 1.3] per 1-year increase, p = 0.033), gender (-25.1% [-42; -3.2] in women, p = 0.029), and nasal polyposis (+38.1% [11.6; 70.9], p = 0.004). No association was observed between CCL18 level and the other main phenotypic characteristics of asthma.Conclusions: Our exploratory study suggests that CCL18 is not an effective biomarker of allergic asthma endotype but may rather be a biomarker of tissue eosinophilia as supported by its association with nasal polyposis.

Keywords: Asthma; CCL18; allergic; biomarker; chemokine; endotype; phenotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Asthma* / diagnosis
  • Biomarkers
  • Chemokines
  • Chemokines, CC
  • Cross-Sectional Studies
  • Female
  • Humans
  • Ligands
  • Male
  • Nasal Polyps*

Substances

  • Biomarkers
  • CCL18 protein, human
  • Chemokines
  • Chemokines, CC
  • Ligands